Pharmaceuticals

Pharvaris BV

Pharvaris BV released FY2026 Q1 earnings on May 12 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -0.6876 (forecast USD -0.8352)

Pharvaris BV released FY2025 Q4 earnings on April 2, 2026 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.843 (forecast USD -0.735)

Pharvaris BV released FY2025 annual earnings on April 2, 2026 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.422 (forecast USD -3.2602)

Pharvaris BV released FY2025 9 Months Earnings on November 12 (EST), actual revenue USD 0, actual EPS USD -2.5936

Pharvaris BV released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6995 (forecast USD -0.7555)

Pharvaris BV released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9715 (forecast USD -0.9016)

Pharvaris BV released FY2025 Semi-Annual Earnings on August 12 (EST), actual revenue USD 0, actual EPS USD -1.8948

Pharvaris BV released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9206 (forecast USD -0.9178)

Pharvaris BV released FY2024 Q4 earnings on April 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6655 (forecast USD -0.7379)

Pharvaris BV released FY2024 annual earnings on April 7, 2025 (EST), with actual revenue USD 0 (forecast USD 0) and actual EPS USD -2.6734 (forecast USD -2.8759)

Pharvaris BV released FY2024 Q3 earnings on November 13 (EST), with actual revenue of 0 USD (forecast 0 USD) and actual EPS of -0.8613 USD (forecast -0.6668 USD)

Pharvaris BV released FY2024 Cumulative Q3 Earnings on November 13, 2024 (EST), Net Income -108.66M USD, EPS -2.0143

Pharvaris Launches CHAPTER-3 Study

Pharvaris BV released FY2023 Q2 earnings on August 7, 2023 (EST), with actual revenue of 0 and EPS of -0.6885 (forecast EPS -0.6581)

Pharvaris BV released FY2022 Q2 earnings on September 12 (EST), actual EPS -0.3925 (forecast -0.5818)

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Vida Global

BiomX

MetaVia

Micware

MicroAlgo

Quantum Cyber NV

PHVS

SBIO

ARKG

LABU

H.C. Wainwright's Patrick Trucchio has reiterated a Buy rating on Pharvaris (PHVS) with a price target of $60.00. Trucchio, who covers the Healthcare sector, has an average return of 27.8% and a 52.26% success rate on his stock recommendations. Additionally, Jonathan Wolleben from Citizens JMP also issued a Buy rating for Pharvaris recently, while Bank of America Securities maintained a Hold rating on the stock.

Tip Ranks

iShares Biotechnology ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

Ark Genomic Revolution ETF

VanEck Biotech ETF

VG Health

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

AtaiBeckley

Definium Therapeutics

Alnylam Pharma

Citizens Financial

Bank of America

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Pharvaris (PHVS) Receives a Buy from H.C. Wainwright

Pharvaris N.V.'s 12-month stock price target has been reduced from $46.85 to $46.6, suggesting a potential upside of 49% based on the May 12 closing price. The consensus rating remains a "Buy" from 14 analysts, with 13 recommending buys and 1 hold. Price forecasts range from $30.9 to $74.02 per share.

TradingView

iShares US Pharma

Pharvaris N.V. Stock 12‑Month Price Target Cut to $46.6, Implies 49% Upside

Pharvaris N.V. has raised approximately US$115 million through a follow-on equity offering of nearly 3.9 million shares at US$29.68 each. This move aims to strengthen the company's cash position amid ongoing losses and upcoming clinical milestones for its drug, deucrictibant. While the capital raise may alleviate balance sheet concerns, it also introduces dilution risks for existing shareholders. Analysts suggest that despite recent declines, Pharvaris shares may still be overvalued, with fair value estimates varying significantly among investors.

Simplywall

The Bull Case For Pharvaris (PHVS) Could Change Following Dilutive US$115 Million Equity Raise - Learn Why

03:59 PM EDT, 05/05/2026 (MT Newswires) -- Peng Lu, Chief Medical Officer, on May 01, 2026, sold 14,166 shares in Pharvaris ( PHVS ) for $427,419. Following the Form 4 filing with the SEC, Lu has control over a total of 66,083 common shares of the company, with 66,083 shares held directly.SEC Filing:: 29.94, Change: -0.08, Percent Change: -0.27 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

fidelity

Pharvaris Insider Sold Shares Worth $427,419, According to a Recent SEC Filing

Anne Lesage, Chief Early Development at Pharvaris N.v., sold 48,300 shares for $1,459,970 on April 29, 2026. Following this transaction, she controls a total of 190,419 common shares, with 56,450 shares held directly and 133,969 shares controlled indirectly, as per a recent SEC filing.

Fidelity

Pharvaris N.v. Insider Sold Shares Worth $1,459,970, According to a Recent SEC Filing

Director Johannes Schikan of Pharvaris N.V. sold 7,100 shares, approximately 1.80% of his holdings, for about $213,000 under a pre-scheduled trading plan. This sale reduces his direct stake to 388,067 shares, valued at around $10.59 million. Investors should focus on upcoming milestones, including pivotal Phase 3 study data and a U.S. NDA submission for their HAE treatments, rather than this minor insider sale. Pharvaris is a clinical-stage biotech company targeting rare diseases, with significant future revenue potential from product approvals.

nasdaq

Netflix

NVIDIA

NVIDIA Corporation

For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next

Pharvaris (NASDAQ:PHVS) experienced a significant increase in trading volume, with 339,252 shares traded, up 96% from the previous session. The stock price rose to $28.65 from $28.22. Analysts have mixed ratings, with Weiss Ratings issuing a 'sell' and HC Wainwright a 'buy' with a $60 target. The company reported a quarterly loss of $0.84 per share, missing estimates. Insiders have sold shares recently, and institutional investors are adjusting their stakes. Pharvaris focuses on developing therapies for rare diseases, particularly hereditary angioedema.

Pharvaris BV(PHVS.US)